Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
54 hedge funds and large institutions have $338M invested in Tourmaline Bio in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 4 reducing their positions, and 14 closing their positions.
550% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 4
338% more capital invested
Capital invested by funds: $77.3M → $338M (+$261M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
57.61% more ownership
Funds ownership: 6.4% → 64.01% (+58%)
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
13% more funds holding
Funds holding: 48 → 54 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$36.3M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$26.7M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$20.2M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$18.1M |
| 5 |
QF
QVT Financial
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$22.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.75M |
| 3 |
Walleye Capital
New York
|
-$738K |
| 4 |
JP Morgan Chase
New York
|
-$687K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
-$547K |
TRML Hedge Fund Activity: Q4 2023 in Review
54 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q4 2023, worth a combined $338M — up 338% from $77.3M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TRML positions and 14 closed out — a net gain of 7 holders — while 26 added to existing stakes and 4 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $36.3M. The largest seller was Blackstone Inc, exiting entirely with an estimated $22.7M sold.
- 54 institutional investors held Tourmaline Bio (TRML) as of Q4 2023, up from 48 in Q3 2023.
- Funds reported $338M of Tourmaline Bio stock for Q4 2023, up 338% quarter-over-quarter.
- 21 funds opened new Tourmaline Bio positions in Q4 2023 and 14 closed out, a net change of +7 holders.
- The largest Tourmaline Bio buyer in Q4 2023 was Deep Track Capital, an estimated $36.3M added.
- The largest Tourmaline Bio seller in Q4 2023 was Blackstone Inc, an estimated $22.7M sold.
Based on aggregated 13F filings for Q4 2023.